Meet The 25-Year Wall Street Veteran Trader Who Says He

New Post Public Reply Private Reply Replies (1) Message Board
AlanC AlanC #141
Meet The 25-Year Wall Street Veteran Trader Who Says He Lost His Job Because Of CYNK

Julia La Roche
Jul. 15, 2014, 11:02 AM
http://www.businessinsider.com/thomas-laresca...z37Yf4Hmyw

Thomas Laresca, a 52-year-old market-maker and father of three, said he lost his Wall Street job because of CYNK Technology — a penny stock that's shocked the internet with its 25,000% rise in just a few weeks.

CYNK Technology is connected to a "social network" site called Introbiz that purports to help people connect to celebrities and business leaders for a fee. However, CYNK does not appear to have ever had assets, revenue, or more than one employee. It has also been a mystery who is behind the company.

CYNK's surging stock drew the attention of the SEC, which halted trading in the stock last Friday citing "concerns regarding the accuracy and adequacy of information in the marketplace and potentially manipulative transactions in CYNK's common stock."

The SEC's move was too late for Laresca, who is now critical of the regulatory agency for being too late to act on CYNK.

Laresca, who first shared his story with Bloomberg News, told us on Tuesday that he resigned from his job as a market-maker with Buckman, Buckman & Reid after racking up "insurmountable" losses from shorting CYNK.

As a market-maker, Laresca's job is to provide liquidity and help match up buyers and sellers of stocks.

Laresca said he watched CYNK go from six cents to $6. Laresca, who has spent 25 years on Wall Street, told us that he thought the stock was a "scam." He shorted the stock thinking the SEC would step in.

"I'd be glad to sell some," he recalled. "When you sell it, you're caught in it."

Eventually, he got caught in a short squeeze as the stock continued to skyrocket. That's because market-makers have to buy back shares every five days, which sends the stock price higher, he explained.

"The day it went from $5 to $15, I was short. The stock kept running. As it runs, there's nothing you can do. You're selling it."

Eventually, his firm decided they didn't want the risk anymore, he said. As a result, he had to buy back the stock and that locked in a loss that was "insurmountable."

"[My firm] did what was right. They took the stock from me. I'm not allowed to trade anymore. I can't have any positions. I don't fault them. They are doing what they had to do."

If he stayed short, he thinks he would have been OK.

Now he's questioning the SEC and why they didn't halt the stock sooner.

"I came home and was trying to explain [CYNK] to my oldest son; he's a smart kid. He'll be a senior at William & Mary. That's when my 10-year-old jumped in and said it was a scam. If a 10-year-old knew it was a scam, why didn't the SEC know?"

He's also going to be looking for another job now. It's unclear if he'll stay in financial services.

"It isn't the end of the world. I've been through cancer and things like that. You just pick your head up and know that God is going to do the right thing," said Laresca.

http://www.businessinsider.com/thomas-laresca...z37Yf4Hmyw
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Savvas Launches Miller & Levine Biology Program Revamp

Updated Category News Views 35

Education Meets Innovation: Savvas Takes a Bold Step Who would have thought biology education could get a makeover that might actually stick? Savvas Learning Company thinks it's onto something with the launch of the all-new Miller & Levine Experience Biology Program. The spotlight's on innovation—it's about time someone shook up the way high schoolers learn biology. A...

Continue Reading
Factory-Built Homes Take Center Stage in New Doc Short

Updated Category News Views 88

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
Data Centers Drive Surge in Power and Cooling Demand

Updated Category News Views 23

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Continue Reading
Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 28

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Jacobi's Harness Brings AI from Concept to Reality

Updated Category News Views 160

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Continue Reading
Air Canada-CAE Scholarship Drives Women in Aviation

Updated Category News Views 88

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 63

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading